Algamed Therapeutics

Company Overview

Snapshot

Founded in August 2014, Algamed Therapeutics operates with 1–10 employees. The company has raised $910K across two funding rounds. In September 2021, Algamed Therapeutics secured funding from PipelBiz.

Business overview

Algamed Therapeutics specializes in developing technologies for treating common vaginal conditions, including dryness, infections, and dyspareunia. Its core product, Secret de Joie, is a natural, hormone-free jelly designed to alleviate vaginal dryness, particularly for breast and ovarian cancer survivors, postmenopausal women, and those with specific medical conditions. The company operates within the Health Tech & Life Sciences sector, focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, serving both B2C and B2B2C markets, with a specific focus on women's health.

Strategic signal

In November 2021, Algamed Therapeutics was highlighted for its innovative approach to femtech solutions, leveraging natural ingredients. This signals a strategic focus on addressing significant women's health issues with non-hormonal alternatives, positioning the company as a key player in the evolving market for natural and patient-friendly therapeutic options.

Company Intelligence Q&A

What is Algamed Therapeutics' primary product?

Algamed Therapeutics' primary product is Secret de Joie, a natural, hormone-free jelly developed to treat vaginal dryness.

When was Algamed Therapeutics founded?

Algamed Therapeutics was founded in August 2014.

What markets does Algamed Therapeutics target?

Algamed Therapeutics targets geomarkets including the United States and Canada.

What is the strategic focus of Algamed Therapeutics' product development?

Algamed Therapeutics focuses on developing technologies dedicated to treating common vaginal conditions, such as dryness and infections, with a particular emphasis on natural and hormone-free solutions like Secret de Joie.